Improving the Standard for Deep Brain Stimulation Therapy: Target Structures and Feedback Signals for Adaptive Stimulation. Current Perspectives and Future Directions

Franz Hell 1, Thomas Köglperger 2, Jan Mehrkens 3, Kai Boetzel 2

1. Neurology, University Hospital, LMU Munich 2. Department of Neurology, LMU University of Munich Hospital 3. Department of Neurosurgery (head of Functional Neurosurgery), Ludwig-Maximilians-University Munich, Germany

Corresponding author: Franz Hell, franz.hell@med.uni-muenchen.de
Disclosures can be found in Additional Information at the end of the article

Abstract

Deep brain stimulation (DBS) is an established therapeutic option for the treatment of various neurological disorders and has been used successfully in movement disorders for over 25 years. However, the standard stimulation schemes have not changed substantially. Two major points of interest for the further development of DBS are target-structures and novel adaptive stimulation techniques integrating feedback signals. We describe recent research results on target structures and on neural and behavioural feedback signals for adaptive deep brain stimulation (aDBS), as well as outline future directions.

Categories: Medical Simulation, Neurology, Neurosurgery
Keywords: dbs target, adaptive dbs, machine learning

Introduction And Background

Deep brain stimulation (DBS) is an established option for the treatment of movement disorders, including essential tremor, Parkinson’s disease and dystonia, and other neurological disorders, such as epilepsy and neuropathic pain. It also is being investigated for psychiatric disorders, i.e., depression, obsessive-compulsive disorder, and Tourette syndrome. DBS has been used successfully in movement disorders for over 25 years; however, the technology has evolved only very slowly and the stimulation scheme (non-adaptive constant stimulation) has not changed at all. To advance DBS technology, two major points of interest are target-structures and novel adaptive stimulation techniques integrating feedback signals [1].

Review

Refined targeting approaches for DBS

An important research area is the definition of brain structures involved in the pathophysiology of the disease to be treated with DBS. Targeting of specific (sub-)structures and fibres involved in the generation of pathological neural activity and avoiding others will be imperative to improve the clinical DBS effect and limiting side-effects. Currently, there are a handful of FDA-approved targets, including the internal segment of the globus pallidus (GPi), nucleus ventralis intermedium (VIM), subthalamic nucleus (STN), and several other investigational targets, used for DBS in movement and other neurological disorders (often more
than one for a specific symptom) [2]. New programming approaches, such as current steering [3], already allow manipulating the volume of tissue activated, and therefore, a more specific stimulation of neural structures and future miniature implants [4] will push this boundary even further.

So far, surgical planning is commonly done based on basic structural MR images and programming is still dependent on trial-and-error guided programming. To better understand the effects of stimulation and guide programming, it is important to refine our theory of neural circuit wiring and their function during normal behaviour and dysfunction in disease. Current research in humans highlights different network structures connected to individual DBS targets and explores oscillatory mechanisms [5] involved in the generation of the pathophysiology of respective symptoms.

Research in dystonia patients has shown that stimulation of the ventral GPi is more efficient in alleviating dystonic symptoms [6]. Rozanski and colleagues used diffusion tensor tractography to study the connectivity patterns of different target structures and specific DBS electrode locations; they reported considerable differences in connectivity profiles of the ventral and dorsal GPi. The authors interpreted their results in favor of different functional subsystems in the ventral and dorsal GPi and recommended that targeting specific areas could play an important role in promoting clinical DBS effects in dystonia [7].

The ViM is a popular target for DBS in medically intractable tremors, like the Parkinsonian or essential tremor. Tractography studies show structural connectivity between ViM and motor cortical, subcortical, cerebellar sites, and the brainstem [8]. Cagnan and colleagues compared subthalamic stimulation near tremor frequency in Parkinson’s disease and stimulation of the ventrolateral thalamus in essential tremor, describing the differences in the response of the behavioural tremor characteristics [9]. The authors reasoned that different networks might be involved in Parkinsonian rest and essential tremor. Several research groups showed the involvement of the dentato-rubro-thalamic tract in the subthalamic region in tremor control [10] and reported successful guidance of DBS surgery with fibre tracking techniques [11].

According to reports, PD patients showed similar improvement in motor function after pallidal as well as subthalamic stimulation [12], while others stated that STN DBS was superior in improving off-drug phase motor symptoms and functioning [13]. Several research groups pointed towards the posterior lateral part of the STN as the preferred DBS target region [1]. The STN was reported to be grouped into a posterolateral motor and a gradually overlapping central associative area, while the limbic area was reported in the anteromedial part of the nucleus [14-16]. Accola et al. used subthalamic local field potential recordings from PD patients to investigate the relation between oscillatory activity, mainly beta activity, and subthalamic fibre connectivity. The area of the STN with the highest beta power, the dorsolateral portion, predominantly projected to the motor, premotor, and also to the limbic and associative areas. Ventral areas associated with connectivity to the medial temporal regions (e.g., amygdala and hippocampus) [5]. It has been shown before that beta power correlates with bradykinesia and rigidity [17-18]. Different research groups [19-23] suggest that the posterior lateral subthalamic area with the most beta activity might be a sweet spot to guide DBS electrode placement. Several groups also report that DBS of the medial and limbic STN can result in the stimulation of the medial forebrain bundle and can induce side effects, such as hypomania [20, 24].

Understanding the functionality of different target structures and their network connectivity is imperative to further improve targeting. At this time, there is an ongoing debate about the real parcellation of the STN, its connectivity, and functional relevance of different subsystems [25]. To a degree, this can be said for every major DBS target [26-27]. Advances in structural imaging...
methods, such as ultra-high field MRI and novel data analysis algorithms, inspired by machine
learning approaches, such as deep learning [28-29], will ultimately refine our understanding
and conception of different neural structures and their wiring in health and disease. New
stimulation techniques, such as non-invasive deep brain stimulation via temporally interfering
electric fields [30], and advances in functional brain imaging and analysis methods [31-
32] could provide a novel way to find and elaborate target structures and help individualize
surgery planning and stimulation. To further advance our understanding, the study of network
dynamics in humans and animal models during behaviour and their relation to the
pathophysiology of the disorder as well as the manipulation of neural circuits with methods,
such as electric or optogenetic stimulation, will provide further insights into the neural
mechanisms, potential target structures, and effects of DBS.

New stimulation schemes for DBS
Neurostimulation systems available today provide stimulation in an open-loop manner, which
means that stimulation settings are pre-programmed and do not automatically respond to
changes in the patient’s clinical symptoms or in the underlying neural substrate. While open-
loop stimulation paradigms remain state of the art, limitations (like overall efficiency or side-
effects) have become more evident as clinical experience grows. Adjusting therapy remains
time-consuming, requiring physicians to evaluate countless combinations of stimulation
parameters to achieve the "best" therapy. Current DBS practice requires patients to follow-up
for months postoperatively to optimize therapy. In the future, feedback signals will ideally be
integrated into closed-loop stimulation systems that rapidly respond to real-time patient needs
and obviate the need for human programming.

Ideally, patient and disease-specific biomarkers could help optimize and individualize therapy,
help to find the optimal parameters for stimulation, and ultimately, close the loop. Local field
potentials with their high temporal resolution, as well as spatial specificity, can easily be
measured with DBS electrodes or implanted neural sensors and hold great promise as such
biomarkers. Several oscillatory patterns in different structures, such as aberrant subcortical
tremor and beta-frequency activity [17, 33-35], pathological cross-frequency coupling [36-37],
or pathological coherence of neural activity between cortical and subcortical structures [38],
have been reported to be correlated with clinical symptoms. Initial approaches incorporating
local field potentials (LFP) as feedback signals into adaptive DBS using beta frequency
amplitude power to trigger stimulation [39] could show clinical improvement of symptoms
compared to standard DBS. A new approach by Tinkhauser et al. targeted potentially
pathological beta bursts with long duration sparing, presumably functionally relevant short
beta bursts, and could show a similar improvement [40]. Despite early success, challenges have
yet to be overcome. Beta power in the STN, for example, correlates with rigidity and
bradykinesia but not with tremor [41-42], which is linked to low-frequency activity at tremor
frequency. PD patients, for example, often show multiple symptoms; a single one-dimensional
biomarker might, therefore, be only partly useful. Most neural biomarkers (like elevated beta
frequency oscillations) are not only correlated with disease symptoms but are also reactive to
medication [43-44], are functionally relevant and modulated during normal behaviour (i.e.,
movement or cognition) [45-46], and evolve with disease progression.
General closed loop DBS for adaptive adjustment of deep brain stimulation (DBS) parameters based upon real time patient measurements, such as electrophysiological signals (LFP, M/EEG, EMG), neurochemical parameters and behavioural measurements and machine learning. First, features from different possible signal sources are learned (e.g. beta frequency amplitude, phase of tremor oscillations) using deep learning approaches to classify between different behavioural (clinical) states (e.g. bradykinesia, tremor) and corresponding neural states. Then, actual states are compared with ideal states and stimulation parameters are adjusted and finally learned via reinforcement learning. In this closed-loop scheme, the stimulation parameters are adjusted within clinical limits based upon the difference between actual neural/behavioural and desired neural/behavioural state.

Body measurements during rest and behaviour (allowing for the assessment of behaviour and symptom severity) could be a promising alternative or additional feedback signal for use in aDBS. Kinematic parameters can be extracted from signals collected by inertial sensor units and then be used to quantify clinical symptoms, such as tremor, rigidity, or bradykinesia. Inertial sensor measurements have already been successfully used for adaptive stimulation in essential...
tremor [47]. Singh and colleagues suggested that gait parameters are affected by DBS surgery [48]. We propose that by integrating electrophysiological recordings and information from kinematic measurements and other sensors like electromyography, the state of the patient, the severity of disease symptoms, and related neural activity can be ultimately learned and classified [49]. As an example, it is conceivable that an algorithm can learn to extract features from neural recordings, such as aberrant beta frequency activity, and relate them to kinematic parameters describing bradykinesia or rigidity as measured during a simple movement task in a calibration setting (for a schematic depiction, see Figure 1). Stimulation parameters can then be varied within clinical limits, and those parameters that are associated with optimal behavioural and neural parameters could then be learned via reinforcement learning. Alternative stimulation protocols, steering the volume of tissue activated (VTA) via segmented leads and parameters like stimulation intensity, frequency, temporal stimulation pattern [50], pulse duration, and timing of stimulation relative to neural activity could be tested and an optimal parameter setting ultimately be learned and adjusted, when needed, closing the loop. As a first step, it is important to establish approaches to guide current steering based on structural as well as functional imaging and behavioural assessment. A future direction could be to collect standardized kinematic and behavioural measurements, together with neural recordings and imaging on a large scale basis, during feedback-guided DBS programming to establish a comprehensive data basis. To establish a real-time link between behavioural and neural measurements, a data analysis model has to be able to extract features from both sources and reliably decode clinical symptom severity as well as find predictors for changes in behaviour in physiological measurements. Large-scale datasets could provide the means to establish and validate such models and could ultimately help establishing adaptive DBS paradigms, closing the loop.

Conclusions

Neither DBS targeting nor stimulation schemes have changed substantially over the last 25 years. To improve DBS therapy and targeting of specific volumes, it will be important to further understand the functional importance of different target areas as well as their structural connectivity and involvement in the genesis of behaviour and clinical symptoms. Finding neural biomarkers for different disease symptoms, as well as the description of their functional involvement during behaviour, will be critical for the further development of closed-loop DBS paradigms. To establish such paradigms, data analysis models that can learn to extract and relate individual neural features to individual clinical symptoms have to be developed and validated. A large-scale comprehensive and standardized dataset incorporating behavioural, as well as neural measurements, could help in developing such models.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Thompson JA, Lantin D, Ince NF, Abosch A: Clinical implications of local field potentials for understanding and treating movement disorders. Stereotact Funct Neurosurg. 2014, 92:251-63. 10.1159/000364913
2. Johnson MD, Miocinovic S, McIntyre CC, Vitek JL: Mechanisms and targets of deep brain stimulation in movement disorders. Neurotherapeutics. 2008, 5:294-308. 10.1016/j.nurt.2008.01.010

3. Timmermann L, Jain R, Chen L, et al.: Multiple-source current steering in subthalamic nucleus deep brain stimulation for Parkinson’s disease (the VANTAGE study): A non-randomised, prospective, multicentre, open-label study. Lancet Neurol. 2015, 14:693-701. 10.1016/S1474-4422(15)00087-3

4. Seo D, Neely RM, Shen K, et al.: Wireless recording in the peripheral nervous system with ultrasonic neural dust. Neuron. 2016, 91:529-39. 10.1016/j.neuron.2016.06.054

5. Accolla EA, Herrojo Ruiz M, Horn A, et al.: Brain networks modulated by subthalamic nucleus deep brain stimulation. Brain. 2016, 139:2503-15. 10.1093/brain/aww250

6. Tisch S, Zrinzo L, Limousin P, et al.: Effect of electrode contact location on clinical efficacy of pallidal deep brain stimulation in primary generalised dystonia. J Neurol Neurosurg Psychiatry. 2007, 78:1314-19. 10.1136/jnnp.2006.109694

7. Rozanski VE, Vollmar C, Cunha JP, et al.: Connectivity patterns of pallidal DBS electrodes in focal dystonia: a diffusion tensor tractography study. Neuroimage. 2014, 84:435-42. 10.1016/j.neuroimage.2013.09.009

8. Klein JC, Barbe MT, Seifried C, et al.: The tremor network targeted by successful VIM deep brain stimulation in humans. Neurology. 2012, 78:787-95. 10.1212/WNL.0b013e318249f702

9. Cagnan H, Little S, Foltynie T, et al.: The nature of tremor circuits in parkinsonian and essential tremor. Brain. 2014, 137:5223-34. 10.1093/brain/awu250

10. Groppa S, Herzog J, Falk D, et al.: Physiological and anatomical decomposition of subthalamic neurostimulation effects in essential tremor. Brain. 2014, 137:109-21. 10.1093/brain/awt304

11. Coenen VA, Varkuti B, Parpaley Y, et al.: Postoperative neuroimaging analysis of DRT deep brain stimulation revision surgery for complicated essential tremor. Acta Neurochir Wien. 2017, 159:779-87. 10.1007%2Fs00701-017-3154-z

12. Follett KA, Weaver FM, Stern M, et al.: Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2010, 362:2077-91. 10.1056/NEJMoa0907083

13. Odekerken VJJ, Boel JA, Schmand BA, et al.: GPI vs STN deep brain stimulation for Parkinson disease: three-year follow-up. Neurology. 2016, 86:755-61. 10.1212/WNL.0000000000002401

14. Plantinga BR, Temel Y, Duchin Y, et al.: Individualized parcellation of the subthalamic nucleus in patients with Parkinson’s disease with 7T MRI. Neuroimage. 2016, 168:403-11. 10.1016/j.neuroimage.2016.09.025

15. Lambert C, Zrinzo L, Nagy Z, et al.: Confirmation of functional zones within the human subthalamic nucleus: Patterns of connectivity and sub-parcellation using diffusion weighted imaging. Neuroimage. 2012, 60:83-94. 10.1016/j.neuroimage.2011.11.082

16. Jahanshahi M, Obeso J, Rothwell JC, Obeso JA: A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition. Nat Rev Neurosci. 2015, 16:719-32. 10.1038/nrn4038

17. Kühn AA, Kupsch A, Schneider GH, Brown P: Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson’s disease. Eur J Neurosci. 2006, 23:1956-60. 10.1111/j.1460-9568.2006.04717.x

18. Tan H, Pogosyan A, Anzak A, et al.: Frequency specific activity in subthalamic nucleus correlates with hand bradykinesia in Parkinson’s disease. Exp Neurul. 2013, 240:122-29. 10.1016/j.expneurol.2012.11.011

19. Horn A, Neumann WJ, Degen K, et al.: Toward an electrophysiological ‘sweet spot’ for deep brain stimulation in the subthalamic nucleus. Hum Brain Mapp. 2017, 38:3577-90. 10.1002/hbm.23594

20. Welter ML, Schüpbach M, Czernecki V, et al.: Optimal target localization for subthalamic stimulation in patients with Parkinson disease. Neurology. 2014, 82:1352-61. 10.1212/WNL.000000000000315

21. Coenen VA, Prescher A, Schmidt T, et al.: What is dorso-lateral in the subthalamic Nucleus (STN)? - A topographic and anatomical consideration on the ambiguous description of today’s primary target for deep brain stimulation (DBS) surgery. Acta Neurochir (Wien). 2008, 150:1163-65. 10.1007/s00701-008-0136-x

22. Vertinsky AT, Coenen VA, Lang DJ, et al.: Localization of the subthalamic nucleus: optimization with susceptibility-weighted phase MR imaging. AJNR Am J Neuroradiol. 2009, 30:1717-24. 10.3174/ajnr.A1669

23. Claire F, Maubon A, Moreau JJ, Cuny E: The mamillothalamic tract is a good landmark for the
anterior border of the subthalamic nucleus on axial MR images. Stereotact Funct Neurosurg. 2011, 89:286-90. 10.1159/000329556

24. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1227/01.NEU.0000345631.54446.06

25. Lambert C, Zrinzo L, Nagy Z, et al.: Do we need to revise the tripartite subdivision hypothesis of the human subthalamic nucleus (STN)? Response to Alkemade and Forstmann. Neuroimage. 2015, 110:1-2. 10.1016/j.neuroimage.2015.01.058

26. Cheung T, Noecker AM, Alterman RL, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

27. Lambert C, Zrinzo L, Nagy Z, et al.: Do we need to revise the tripartite subdivision hypothesis of the human subthalamic nucleus (STN)? Response to Alkemade and Forstmann. Neuroimage. 2015, 110:1-2. 10.1016/j.neuroimage.2015.01.038

28. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

29. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

30. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

31. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

32. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

33. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

34. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

35. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

36. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

37. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

38. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

39. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

40. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

41. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

42. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

43. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187

44. Coenen VA, Honey CR, Hurwitz T, et al.: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson’s disease. Neurosurgery. 2009, 64:1106-14. 10.1002/ana.24187
45. Foffani G, Bianchi AM, Baselli G, Priori A: Movement-related frequency modulation of beta oscillatory activity in the human subthalamic nucleus. J Physiol. 2005, 568:699-711. 10.1113/jphysiol.2005.089722

46. Herz DM, Zavala BA, Bogacz R, et al.: Neural correlates of decision thresholds in the human subthalamic nucleus. Curr Biol. 2016, 26:916-20. 10.1016/j.cub.2016.01.051

47. Cagnan H1, Brittain JS, Little S, et al.: Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation. Brain. 2013, 136:3062-75. 10.1093/brain/awt239

48. Singh A, Kammermeier S, Mehrkens JH, Bötzel K: Movement kinematic after deep brain stimulation associated microlesions. J Neurol Neurosurg Psychiatry. 2012, 83:1022-26. 10.1136/jnnp-2012-302309

49. Schirrmöster RT, Springenberg JT, Fiederer LDJ, et al.: Deep learning with convolutional neural networks for EEG decoding and visualization. Hum Brain Mapp. 2017, 38:5391-5420. 10.1002/hbm.23730

50. Zeitler M, Tass PA: Augmented brain function by coordinated reset stimulation with slowly varying sequences. Front Syst Neurosci. 2015, 9:49. 10.3389/fnsys.2015.00049